The partner notification service is part of a public health initiative to help protect the public and limit the spread of STIs.

When you choose to use this service to inform one or more sexual partners that you’ve been diagnosed with an STI, you are acting privately and anonymously, as well as individually and of your own volition, in a spirit of goodwill and respect, and with full knowledge of the potential consequences.

Your aim is to inform each person you contact of your diagnosis, in order to encourage them to see a doctor. Once you’ve sent a message, it cannot be changed. Please read the Legal Note before using this service.

HIV — Treating children is challenging

January 15 2013

KIRKLAND, QC, Jan. 15, 2013 /CNW Telbec/ — Despite significant therapeutic advances in the treatment of HIV/AIDS in Canada and around the world, treating children with HIV can be especially challenging.

"One of the biggest challenges we physicians face in treating people infected with HIV, particularly children, is getting them to take their medications as prescribed. Adherence to HIV therapy is vital to prevent the virus from developing resistance to life-saving drugs," said Christos Karatzios MD, Assistant Professor of Pediatrics in the Division of Infectious Diseases, Montreal Children's Hospital. "When the virus becomes resistant the drug is no longer effective and new ones have to be available, or else treatment fails."

Merck Canada announced today that ISENTRESS® (raltegravir) is now approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced children and adolescents two years of age and older. Chewable tablets will be available to children two to 11 years of age.1

"The approval of raltegravir for kids with HIV is important because it provides pediatricians with a new drug that is known from its use in adults and recent studies in children, to be well-tolerated with a good safety profile," continued Dr. Karatzios. "A number of children find that some current HIV drug therapies taste bad and subsequently refuse to take their medications altogether, or vomit after swallowing them."

Raltegravir is a palatable chewable HIV drug available for children
According to Dr. Karatzios, "Taste can be a real barrier to kids taking their meds, especially when they're between the ages of two and ten. If it tastes bad they don't want to take it. Doctors now have a new HIV drug therapy that we expect children will take more readily. This is good news, because no physician wants to see a child and the family suffer with the consequences of untreated HIV."

How children contract HIV
Mother-to-child transmission of HIV can occur during gestation (in utero transmission) or during delivery when the newborn comes into contact with maternal blood and cervical-vaginal secretions. In the absence of any intervention, it is estimated that 25% of pregnant women who are HIV positive will transmit the virus to their infant either during pregnancy or at birth. If a seropositive mother breastfeeds her baby, the risk of transmission increases to an estimated 35%.

Although there has been a decline in the rate of mother-to-child transmission of HIV, the absolute number of infants exposed to HIV in utero or during birth is on the rise.